Risperdal Consta Stungulyfsstofn og leysir, forðadreifa 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

risperdal consta stungulyfsstofn og leysir, forðadreifa 50 mg

janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg

Risperdal Consta Stungulyfsstofn og leysir, forðadreifa 37,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

risperdal consta stungulyfsstofn og leysir, forðadreifa 37,5 mg

janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg

Risperdal Consta Stungulyfsstofn og leysir, forðadreifa 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

risperdal consta stungulyfsstofn og leysir, forðadreifa 25 mg

janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg

Sporanox Hart hylki 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sporanox hart hylki 100 mg

janssen-cilag ab - itraconazolum inn - hart hylki - 100 mg

Concerta Forðatafla 18 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 18 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 18 mg

Concerta Forðatafla 27 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 27 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 27 mg

Concerta Forðatafla 36 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 36 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 36 mg

Concerta Forðatafla 54 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

concerta forðatafla 54 mg

janssen-cilag ab - methylphenidatum hýdróklóríð - forðatafla - 54 mg

Azacitidine Celgene Evrópusambandið - íslenska - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Haldol Depot Stungulyf, lausn 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

haldol depot stungulyf, lausn 100 mg/ml

essential pharma limited - haloperidolum dekanóat - stungulyf, lausn - 100 mg/ml